PSIL 025
Alternative Names: PSIL-025Latest Information Update: 17 May 2024
At a glance
- Originator Psilera
- Class Antidementias; Neuropsychotherapeutics; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Anxiety disorders
Most Recent Events
- 02 May 2024 Psilera has patents pending for PSIL 025 (Psilera pipeline May 2024)
- 02 May 2024 Preclinical trials in Anxiety disorders in USA (unspecified route) prior to May 2024 (Psilera pipeline, May 2024)